VT-1598

novel broad-spectrum fungal CYP51 inhibitor

Also Known As:

4-((4-((6-(2-(2,4-Difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1H-tetrazol-1-yl)propyl)-3-pyridinyl)ethynyl)phenoxy)methyl)benzonitrile; Benzonitrile, 4-((4-(2-(6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1H-tetrazol-1-yl)propyl)-3-pyridinyl)ethynyl)phenoxy)methyl)-

Networked: 6 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Tetrazoles: 14
      - VT-1598: 6
  - Pyridines: 88
    - VT-1598: 6

Experts

1.	Garvey, Edward P: 4 articles (01/2019 - 01/2018)
2.	Schotzinger, Robert J: 4 articles (01/2019 - 01/2018)
3.	Yates, Christopher M: 4 articles (01/2019 - 01/2018)
4.	Wiederhold, Nathan P: 3 articles (01/2019 - 01/2018)
5.	Garvey, E P: 2 articles (06/2020 - 10/2018)
6.	Schotzinger, R J: 2 articles (06/2020 - 10/2018)
7.	Sharp, A D: 2 articles (06/2020 - 10/2018)
8.	Warn, P A: 2 articles (06/2020 - 10/2018)
9.	Yates, C M: 2 articles (06/2020 - 10/2018)
10.	Catano, Gabriel: 2 articles (01/2019 - 01/2018)

Related Diseases

1.	Coccidioidomycosis 01/01/2018 - "We evaluated the in vivo efficacy of VT-1598 in murine models of central nervous system coccidioidomycosis caused by C. " 01/01/2018 - "This in vivo efficacy supports human studies to establish the utility of VT-1598 for the treatment of coccidioidomycosis." 01/01/2018 - "The Novel Fungal Cyp51 Inhibitor VT-1598 Is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by Coccidioides posadasii and Coccidioides immitis."
2.	Candidiasis (Moniliasis) 01/01/2018 - "To determine the efficacy of VT-1598 in the treatment of oral Candida infection caused by fluconazole-susceptible and -resistant clinical isolates. "
3.	Infections 10/01/2018 - "When VT-1598 was dosed in the survival study, no VT-1598-treated animal succumbed to the infection. " 06/01/2020 - "These data strongly support further exploration of VT-1598 for the treatment of this lethal mold infection." 01/01/2019 - "These results suggest that VT-1598 may be a future option for the treatment of invasive infections caused by C. " 10/01/2018 - "These pre-clinical in vivo data strongly support clinical investigation of VT-1598 as a novel therapy for this lethal infection." 01/01/2018 - "Tongue fungal load was determined in IL-17 signalling-deficient Act1-/- mice following sublingual Candida albicans infection and oral treatment with fluconazole or VT-1598. "
4.	Cryptococcal Meningitis 10/01/2018 - "The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitis."
5.	Mycoses (Diseases, Fungus) 01/01/2019 - "The fungal Cyp51-specific inhibitors VT-1161 and VT-1598 have emerged as promising new therapies to combat fungal infections, including Candida spp. To evaluate their in vitro activities compared to other azoles, MICs were determined by Clinical and Laboratory Standards Institute (CLSI) method for VT-1161, VT-1598, fluconazole, voriconazole, itraconazole, and posaconazole against 68 C. "

Related Drugs and Biologics

1.	Fluconazole (Zonal)
2.	Voriconazole (Vfend)
3.	Interleukin-17 (Interleukin 17)
4.	Itraconazole (Sporanox)
5.	Azoles
6.	Caspofungin (Cancidas)
7.	posaconazole
8.	liposomal amphotericin B
9.	VT-1161

Related Therapies and Procedures

1.	Therapeutics